20 Feb 2020 - 21 Feb 2020 | Leuven, Belgium

Agenda

Thursday
20 Feb 2020
16:00 – 17:00
Registration/Coffee
17:00 – 17:05
Auditorium
Welcome by the Vice-Governor of Flemish Brabant

Ms. Ann Schevenels, Vice-Governor Economy

17:05 – 17:10
Auditorium
Introduction by the Chairman

Mr. Jan Schrooten, Co-Founder & CEO of Antleron

17:10 – 17:40
Auditorium
Keynote speaker 1

'AI and precision medicine - Moving from monogenic to oligogenic pathogenicity predictions' by Prof. Dr. Tom Lenaerts of ULB and VUB

17:40 – 18:10
Auditorium
Keynote speaker 2

'New opportunities for silicon nanotechnologies in personalized therapies' by Dr. Olivier Henry, Program Manager Life Sciences and Medical Device Technologies of imec

18:10 – 21:00
Room 'Spoor 95'
Walking Dinner
Friday
21 Feb 2020
08:30 – 09:30
Registration/Coffee
09:30 – 09:35
Auditorium
Welcome by the Vice-Governor of Flemish Brabant

Mr. Tom Dehaene, Vice-Governor Internationalization

09:35 – 09:45
Auditorium
Introduction by the Chairman

Mr. Jan Schrooten, Co-Founder & CEO of Antleron

09:45 – 10:05
Auditorium
Keynote speaker 1

‘The serendipitous discovery of novel microsatellite instability biomarkers’ by Prof. Dr. Diether Lambrechts, PhD, director of VIB-KU Leuven Center for Cancer Biology

      10:05 – 10:25
      Auditorium
      Keynote speaker 2

      'Science in the Space Environment - SciSpacE ' by Ms. Thu Jennifer Ngo-Anh, SciSpacE Team Leader at the European Space Agency



      10:25 – 11:00
      Room 'Spoor 95'
      Coffee break & Matchmaking
      Matchmaking
      11:00 – 12:30
      Room 'Spoor 95'
      Matchmaking
      Matchmaking
      11:00 – 12:30
      Auditorium
      Session 1: Personalized Medicine in Belgium/Flanders

      Being the European hot spot for life sciences innovation, Flanders has identified personalized medicine as an innovation priority within its smart specialization strategy and aims to support translation of ideas to the patient that are enabled by such things as biomarker discovery and validation, data gathering and analytics, digital modelling and prediction of medical interventions, smart implantables, advanced manufacturing techniques for personalized drugs or prosthesis, artificially intelligent diagnosis and smart logistics. Flanders is taking the lead in personalized medicine by fueling collaborative innovation within the Flemish bio-, nano- and med-tech sector to capture the unique opportunities in the transformation of personalized medicine.

      • 'Modeling amyotrophic lateral sclerosis (ALS) by creating human neuromuscular junctions in a dish' by Prof. Dr. Ludo Van Den Bosch, Group Leader VIB-KU Leuven Center for Brain & Disease Research
      • 'Home monitoring: the missing link' by Mr. Jan-Willem Hoste, COO at Antelope DX
      • ‘Microchips enable GMP in a box for personalized cancer therapies’ by Ms. Sarah Schreurs, Pharmaceutical Consultant at Quality by Design and Mr. Maarten Fauvart, R&D Team Leader - Senior Scientist Life Science at imec
      • 'Innovation through co-creation: a case study in Flanders' by Mr. Tim Van Cleynenbreugel, Director of Business Development - Life Sciences at Comate and Mr. Bart Landuyt founder of CellSine
      11:00 – 12:30
      Raadszaal
      Session 2: Personalized Medicine in Belgium/Wallonia

      As Wallonia emerges as a world class biotech and medtech hub, the region wants to accelerate innovation. With life sciences being a key growth sector, Wallonia enhances the development of the biopharmaceutical and medtech ecosystem by bringing together all the actors involved in innovation in this area. In line with the principles of smart specialization, Wallonia focuses on six technological target areas for which the Walloon region has a critical mass of global players: biopharmacy, cell therapy, radiation applied to health, medical devices and in vitro diagnostics, biomanufacturing and data-driven science.

      • 'Data-driven excellence in biomanufacturing' by Mr. Thibault Helleputte, CEO of DNAlytics
      • 'The role of radiomics in oncology treatment’ by Mr. Wim Vos, CEO of Oncoradiomix
      • 'AI and photonics technologies for personalized medicine. Some practical examples ' by Ms. Anne-Sophie Bridoux, Research Project Manager of Multitel and Mr. Fabian Dortu, Group Leader Biophotonics at Multitel
      • 'Connecting People with Parkinson’s disease with their care team for a better quality of life at lower cost' by Mr. Benoit Tas, CEO of Neuropath
      12:30 – 13:30
      Room 'Spoor 95'
      Lunch
      12:30 – 13:30
      Room 'Spoor 95'
      Matchmaking (during lunch)
      Matchmaking
      13:30 – 15:00
      Room 'Spoor 95'
      Matchmaking
      Matchmaking
      13:30 – 15:00
      Raadszaal
      Session 1: Personalized Medicine in Space

      The space sector is evolving rapidly and is ready to reach out to other important economic sectors. This is also the case for the Flemish space industry. By combining the leading position of Flanders in biotechnology with the knowhow of the Flemish space actors in microgravity research, the session will examine how cross-innovation between both can lead to innovative solutions, products and proofs of concept. A particular emphasis will be put on the available options for research in the International Space Station (ISS) and on how technology transfer for diagnosis can be realized.

      • 'Why space for personalized medicine - Life-on-chip and how to access' by Ms. Hilde Stenuit, Research Space Access - Commercial Innovation ICE Cubes Service
      • 'Life Sciences, your Portal to the Space Market' by Mr. Dries Demey, Senior System Engineer at QinetiQ Space
      • ‘Technology transfer: Applying space technology within medicine in the past, present and future’ by Mr. Pieter Deleye, Business Development Manager TechXfer of Verhaert
      • 'Microphysiological Organ-on-a-Chip platforms: Towards a paradigm change in non-clinical drug development and toxicity screening' by Dr. Madalena Cipriano, PharmD at Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB (Germany)
      • 'Ground-based platforms for space research: usefulness in personalized medicine’ by Mr. Kevin Tabury, Scientific Collaborator at SCK-CEN
      13:30 – 15:00
      Auditorium
      Session 2: Personalized Medicine in the Neighboring Countries

      Within the pharmaceutical and medical world personalized patient care is a key trend in Europe and on an international level. The potential is huge, for patients and sector alike. Partnerships are essential to realize the potential of personalized medicine. Hence, on different levels multi-stakeholder collaborations are emerging that build on vivid ecosystems combining biomedical, technological and data driven expertise.
      Further strengthening these ecosystems, based on regional and complementary smart specialization, will enable even more in-depth cross-over collaborations and as such build long-term roadmaps across ecosystems that will assist in materializing the potential of PM in our regions, in Europe and in space.

      • 'CMOS and MEMS technologies to enable personalized medicine' by Mr. Ulrich Bretthauer, Product Marketing Manager Medical of X-FAB Semiconductor Foundries (Germany)
      • 'Building Vessels on a chip to model genetic vascular diseases using patient-specific iPSCs' by Prof. Dr. Valeria Orlova, Assistant Professor at the Department of Anatomy and Embryology of Leiden University Medical Center (The Netherlands)
      • 'Mono layer graphene for bioelectronics: applications to wound healing monitoring' by Mr. Vincent Bouchiat, CEO of Grapheal (France)
      • 'Automation and Robotics to enable Personalized Medicine' by Mr. Guido Pistolesi System Engineer at Inpeco (Italy)
      15:00 – 15:30
      Room 'Spoor 95'
      Matchmaking (during coffee break)
      Matchmaking
      15:30 – 16:30
      Auditorium
      Financing avenues for 'Life-on-Chip' ventures
      • 'EIT Health: Gateway to International Growth' by Mr. Bart Haex, Business Creation Manager Belgium - The Netherlands at EIT Health
      • 'Science in the Space Environment - SciSpacE - How to get involved' by Mr. Leonardo Surdo, Project Scientist at the European Space Agency
      • 'Non-Dilutive Funding and Beyond’  by Dr. Marc Van de Craen, Managing Director at BiotechSubsidy
      16:30 – 16:45
      Auditorium
      Key findings Life-on-Chip
      16:45 – 18:00
      Koffiehoek
      Reception
      The event agenda's time zone is CEST.